METHODS: Our study included 284 patients diagnosed with the International Federation of Gynecology and Obstetrics stage 1A/1B EEC in our center from 2010 to 2018. The clinicopathological characteristics of the patients were obtained retrospectively from their electronic files.
RESULTS: The median age of the patients was 60 years (range 31-89). The median follow-up time of the patients was 63.6 months (range 3.3-185.6). Twenty-two (7.74%) patients relapsed during follow-up. Among the relapsed patients, 59.1% were at stage 1A ECC, and 40.9% were at stage 1B. In our study, the one-, three-, and five-year recurrence-free survival (RFS) rates were 98.9%, 95.4%, and 92.9%, respectively. In the multivariate analysis, grade and tumor size were found to be independent parameters of RFS in all stage 1 EEC patients. Furthermore, the Ki-67 index was found to affect RFS in stage 1A EEC patients, and tumor grade affected RFS in stage 1B EEC patients. In the time-dependent receiver operating characteristic curve analysis, the statistically significant cut-off values were determined for tumor size and Ki-67 index in stage 1 EEC patients.
CONCLUSIONS: Stage 1-EEC patients in the higher risk group in terms of tumor size, Ki-67, and grade should be closely monitored for recurrence. Defining the prognostic factors for recurrence in stage 1 EEC patients may lead to changes in follow-up algorithms.
方法:我们的研究包括2010年至2018年在我们中心诊断为国际妇产科联合会1A/1BEEC期的284例患者。回顾性地从他们的电子文件中获得了患者的临床病理特征。
结果:患者的中位年龄为60岁(范围31-89岁)。患者的中位随访时间为63.6个月(范围3.3-185.6)。22例(7.74%)患者在随访期间复发。在复发患者中,59.1%处于1AECC阶段,40.9%处于1B阶段。在我们的研究中,Theone-,三-,5年无复发生存率(RFS)为98.9%,95.4%,和92.9%,分别。在多变量分析中,发现分级和肿瘤大小是所有1期EEC患者RFS的独立参数.此外,发现Ki-67指数影响1A期EEC患者的RFS,肿瘤分级影响1B期EEC患者的RFS。在与时间相关的接收器工作特性曲线分析中,在1期EEC患者中,确定了肿瘤大小和Ki-67指数的统计学显著临界值.
结论:就肿瘤大小而言,高风险组的1期-EEC患者,应密切监测Ki-67和级别是否复发。定义1期EEC患者复发的预后因素可能会导致随访算法的变化。